Pro: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”

Jeff S. Healey

doi:10.1160/TH09-06-0369

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2009; 102(05): 912-913
DOI: 10.1160/TH09-06-0369

Pro/Contra Article

Schattauer GmbH

Pro: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”

Jeff S. Healey

¹McMaster University, Hamilton, Ontario, Canada

References
1 Go AS, Hyleck EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001; 285: 2370-2375.
2 Go AS, Hylek EM, Chang Y. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. J Am Med Assoc 2003; 290: 2685-2692.
3 Toghi H, Tajima T, Konno T. et al. The risk of cerebral infarction in nonvalvular atrial fibrillation: Effects of age, hypertension and anti-hypertensive Treatment. Eur Neurol 1991; 31: 126-130.
4 Hart RG, Pearce LA, Aquilar MI. Meta-analysis: Anti-thrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
5 Gasse C, Hollowell J, Meier CR. et al. Drug interactions and risk of acute bleeding leading to hospitalization or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005; 94: 537-543.
6 Pengo V, Legnanai C, Noventa F. et al. ISCOAT Study Group: Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding: A multicenter inception cohort study. Thromb Haemost 2001; 85: 418-422.
7 Go AS, Hylek EM, Borowsky LH. et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927-934.
8 Gallagher AM, Rietbrock S, Plumb J. et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?. J Thromb Haemost 2008; 06: 1500-1506.
9 Nieuwlaat R, Capucci A, Camm AJ. et al. Euro Heart Survey Investigators: Atrial fibrillation management: A prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434.
10 Rietbrock S, Plumb JM, Gallagher AM. et al. How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis from the UK General Practice Research Database. Thromb Haemost 2009; 101: 527-534.
11 Perret-Guillaume C, Wahl DG. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose: A meta-analysis. Thromb Haemost 2004; 91: 394-402.
12 Hughes M, Lip GYH. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost-effectiveness data. Thromb Haemost 2009; 99: 295-304.
13 Fuster V, Ryden LE, Cannom DS. et al. ACC/AHA/ ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2006; 48: 854-906.
14 Connolly S, Pogue J, Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
15 Healey JS, Hart RG, Pogue J. et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke 2008; 39: 1482-1486.
16 Connolly SJ, Pogue J, Eikelboom J. et al. ACTIVE W Investigators: Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centres and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
17 ACTIVE Investigators. Connolly SJ, Pogue J, Hart RG, Hohnloser SH. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 30: 2066-2078.
18 Ezekowitz MD, Connolly SJ, Parekh A. et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin compared with dabigatran. Am Heart J 2009; 157: 805-810.